Fibromyalgia is a major contributor to quality of life in lupus

Journal of Rheumatology

Volumn 24, Issue 11, 1997, Pages 2145-2148

  Gladman, Dafna D ^a,b,c,d,e   Urowitz, Murray B ^a,b,c,d   Gough, Jacqueline ^a,d   MacKinnon, Anne ^a,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Ctr Prognosis Studs Rheum Dis   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Damage; Disease activity; Fibromyalgia; Health status; Quality of life; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMAN; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

ADULT; DISEASE PROGRESSION; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0030724498     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gladman DD: Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:402-8.
2. Bombardier C, Gladman DD, Urowitz MB, Charron D, Chang CH, and The Committee on Prognosis Studies in SLE: The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.
3. Gladman D, Ginzler E, Goldsmith C, et al: The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis Rheum 1996;39:363-9.
4. Stewart AL, Hays RD, Ware JE: The MOS Short-Form general health survey. Med Care 1988;26:724-34.
5. Gladman D, Urowitz M, Ong A, Gough J: A comparison of five health status instruments in patients with systemic lupus erythematosus. Lupus 1996;5:190-5.
6. Ware JE, Sherbourne CD: The MOS 36-item Short-form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
7. Gladman D, Urowitz M, Ong A, Gough J, MacKinnon A: Lack of correlation among 3 outcome measures in SLE: Disease activity, damage and quality of life. Clin Exp Rheumatol 1996;14:305-8.
8. Lee P, Urowitz MB, Bookman AAM, et al: Systemic lupus erythematosus. A review of 110 patients with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
9. Wolfe F, Smythe HA, Yunus MB, et al: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72.
10. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT: The SF-36 health survey questionnaire: An outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
11. Brazier JE, Harper R, Jones NMB, et al: Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992;305:160-4.
12. Middleton GD, McFarlin JE, Lipsky PE: The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994;37:1181-8.
13. Liang MH, Socher SA, Larsen MG, Schur PH: Reliability and validity of 6 systems for the clinical assessment of disease activity in SLE. Arthritis Rheum 1989;32:1107-18.
14. Stoll T, Stucki G, Mailk J, Pyke S, Isenberg D: Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60.
15. Morand EF, Miller MH, Whittingham S, Littlejohn GO: Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus 1994;3:187-91.